How to access Austedo from the UAE — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A UAE patient with chorea associated with Huntington's disease or tardive dyskinesia may receive a prescription for Austedo (deutetrabenazine) from their treating neurologist or psychiatrist. Austedo is FDA-approved for both indications and developed by Teva Pharmaceuticals. It is not a controlled substance. In the UAE, Austedo is not routinely registered for outpatient dispensing, so access is typically coordinated through the named-patient import pathway.
This guide explains the pathway, documentation your physician prepares, typical timing and cost bands, and where Reserve Meds fits in.
The clinical situation
Austedo is an oral vesicular monoamine transporter 2 (VMAT2) inhibitor, dosed twice daily (immediate-release) or once daily (Austedo XR extended-release). Deuteration extends half-life compared with tetrabenazine, allowing lower peak-to-trough swings. Eligibility for Huntington's chorea requires genetic confirmation; eligibility for tardive dyskinesia requires documented exposure to dopamine receptor-blocking agents and persistent involuntary movements. Your neurologist or psychiatrist establishes baseline using standardised movement scales (AIMS, UHDRS-chorea score), screens for depression and suicidality (labelled warning for Huntington's patients), and sets follow-up cadence.
Is Austedo legally importable into the UAE?
Yes — through the UAE Ministry of Health and Prevention (MoHAP) named-patient import framework, with parallel authority through the Department of Health (DoH) in Abu Dhabi and the Dubai Health Authority (DHA) in Dubai depending on where the prescribing facility sits.
The mechanism permits a UAE-licensed physician to import a medicine not locally registered when (a) the medicine is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent registered alternative is suitable, (c) the physician accepts clinical responsibility, and (d) chain of custody is documented. Huntington's chorea and tardive dyskinesia have limited disease-specific registered options in the UAE.
How the pathway works, step by step
- Consultation with your treating neurologist or psychiatrist. Indication documentation, movement-disorder scoring, and clinical rationale.
- Baseline assessment. AIMS or UHDRS-chorea baseline, depression/suicidality screen (for Huntington's), QT review, hepatic function.
- MoHAP named-patient application. The physician or hospital pharmacy files clinical rationale, patient reference, titration plan, and chain-of-custody commitment.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Austedo from authorised distribution under DSCSA.
- Ambient shipment. Austedo ships under controlled ambient conditions with chain-of-custody documentation.
- Arrival and dispensing. The hospital pharmacy releases the bottle with titration and monitoring guidance.
What documentation your physician needs
- Clinical rationale letter confirming indication and Austedo as the indicated therapy
- Verification of UAE medical license
- AIMS or UHDRS-chorea score baseline
- Huntington's genetic confirmation (for chorea indication)
- Depression/suicidality screen (for Huntington's patients, per labeling)
- Planned titration schedule and monitoring plan
Reserve Meds provides a physician documentation kit bundling templates MoHAP reviewers expect for movement-disorder named-patient imports.
Costs and timing
Austedo's US cash-pay reference cost sits in an indicative 2026 annual range of roughly USD 90,000–115,000 depending on titrated dose. International logistics, MoHAP documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a transparent quote at the start of intake. These figures are indicative, not guaranteed.
Indicative timing — not guaranteed — for first dispense after cohort intake opens is approximately 14–28 days from the moment a complete MoHAP application is submitted.
Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
Reserve Meds's role
- Sourcing. Through our US-licensed specialty wholesale partner under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and MoHAP review.
- Logistics. Ambient-controlled shipment to your prescribing hospital.
- Concierge case lead. A named point of contact coordinating monthly refills.
What we do not do: We are not the prescriber, do not practise medicine, and are not the dispensing pharmacy. All clinical decisions remain with your treating physician. We operate on a waitlist basis during pre-launch.
Frequently asked
Is this legal in the UAE? Yes, when executed through the MoHAP / DoH / DHA named-patient framework with appropriate documentation. See our trust and compliance page.
Is Austedo a controlled substance? No. Deutetrabenazine is not a scheduled controlled substance.
How does Austedo compare with Ingrezza or tetrabenazine? All three address movement disorders via VMAT2 inhibition. Austedo (deuterated) and Ingrezza (valbenazine) offer improved tolerability profiles versus first-generation tetrabenazine. Dosing schedules and indications differ; your physician selects based on the clinical picture.
What is the suicidality warning? Austedo carries a labelled warning regarding depression and suicidal ideation/behaviour in Huntington's disease patients. Structured screening before and during therapy is required.
Will insurance cover this? Cash-pay is the default. Some UAE private insurers consider case by case; we supply documentation but do not process claims directly.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we enter intake for Austedo coordination.
Add me to the Austedo waitlist> Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. We are in pre-launch; service availability is limited to our first cohort and published timelines are indicative, not guarantees. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.